(Q37361497)

19 August 2017

1 reference

title

Bladder cancer biomarkers and their role in surveillance and screening (English)

1 reference

19 August 2017

0 references

1 reference

2

Chris H Bangma

1 reference

19 August 2017

author name string

Angela A G Van Tilborg

series ordinal

1

1 reference

19 August 2017

Ellen C Zwarthoff

series ordinal

3

1 reference

19 August 2017

publication date

1 January 2009

1 reference

International Journal of Urology

19 August 2017

published in

1 reference

19 August 2017

volume

16

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

23-30

1 reference

The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Urinary tract infection and patient satisfaction after flexible cystoscopy and urodynamic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Surveillance for bladder cancer: the management of 4.8 million people. South-west Urologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Urine markers for bladder cancer surveillance: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

HA-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Are there molecular signatures for predicting bladder cancer prognosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Survivin expression is associated with bladder cancer presence, stage, progression, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

The role of deoxyribonucleic acid methylation in development, diagnosis, and prognosis of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Tumor suppressor loci in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Functional characterization of the bladder cancer marker, BLCA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Mechanistic analysis of the role of BLCA-4 in bladder cancer pathobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Telomerase activity is correlated with lower grade and lower stage bladder carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Urinary tract cancers found by homescreening with hematuria dipsticks in healthy men over 50 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Dipstick haematuria and bladder cancer in men over 60: results of a community study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Early results of bladder-cancer screening in a high-risk population of heavy smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective Phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Adherence to Surveillance Among Patients With Superficial Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Long-term outcome of home dipstick testing for hematuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Usefulness of liquid-based preparation in urine cytology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Highly specific urine-based marker of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Non-invasive molecular detection of bladder cancer recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: a utility analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02174.X

10.1111/J.1442-2042.2008.02174.X

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference